Using multi-parametric imaging and multi-nuclear cardiac magnetic resonance to investigate novel treatment strategies for heart failure
Abstract
Heart failure (HF) remains the leading cause for hospitalisation in patients over the age of 65 years in industrialised nations. Furthermore, prognosis of HF remains poor and lags behind the improvements observed for similar chronic conditions like cancer, despite efforts for new therapies. However, these therapies are mostly available for patients with HF and a reduced ejection fraction (HFrEF), whereas prognostically relevant therapies for patients with HF and a preserved ejection fraction (HFpEF) have been absent for more than 20 years and this only changed very recently with the results of the EMPEROR-preserved trial investigating treatment with empagliflozin (10 mg once daily) in patients with HFpEF. Equally, a significant improvement of quality of life and physical limitations has been shown for patients with HFpEF following treatment with dapagliflozin in PRESERVED-HF. An increasing amount of evidence describes more subtypes of the complex and rather arbitrarily classified syndrome of HF and thus, there is a growing need for comprehensive, non-invasive imaging techniques to identify and individually phenotype patients affected. Furthermore, the same approach could be used to assess novel treatments as well as identify treatment responders, further tailoring individual patient management and aid efforts to improving prognosis. Additionally, use of a model imaging technique may lower the exponential costs of drug development by reducing the numbers of subjects needing…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 22 participants or records.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.